CAS 93106-60-6 API Pharmaceutical Enrofloxacin Powder Antibiotics

This product is a broad-spectrum bactericide with special effects on mycoplasma. It has bactericidal efficacy against Escherichia coli, Klebsiella pneumoniae, Salmonella, Proteus, Pseudomonas aeruginosa, Haemophilus, Pasteurella multocida, Pasteurella hemolyticus, Staphylococcus aureus, Streptococcus, etc.

Enrofloxacin can be used as an animal drug with a long half life in animals and good tissue distribution. It is a widely effective antibacterial agent that has antibacterial effects against gram-positive bacteria, negative bacteria, and mold forms. It has been used for the control of vibrio and colibacillosis in cultured fish.

This product is a synthetic third generation quinolone antibacterial drug, also known as ethyl. It was approved by the FDA on October 4, 1996 and is a specialized quinolone antibacterial drug for livestock, poultry, and aquatic products. It can bind to bacterial DNA cyclooxygenase subunit A, thereby inhibiting the enzyme's cutting and connecting functions, preventing bacterial DNA replication, and exhibiting antibacterial effects. With broad spectrum antibacterial activity and strong permeability, this product has a strong killing effect on gram negative bacteria, as well as good antibacterial effect on gram positive bacteria. It is well absorbed orally, has a high and stable blood concentration, and can be widely distributed in tissues., which still has a strong antibacterial effect. It has strong antibacterial activity against almost all pathogenic bacteria of aquatic animals. It is effective for severe infections caused by drug-resistant pathogens and has no cross resistance to other antibiotics.